Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2022-12-06 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Quarterly Operational and Strategy Update
Regulatory Filings Classification · 1% confidence The document is titled 'Quarterly Operational and Strategy Update' and provides detailed updates on various evaluation projects, preclinical assets (CLX001, VAL301, BC201), clinical assets (VAL401, VAL201), and a strategy update regarding moving from a virtual biotech model. This content structure—a comprehensive update on operations, pipeline progress, and strategy—is characteristic of an Interim/Quarterly Report (IR), which provides detailed financial and operational performance for a period shorter than a year. Although it is an 'update,' its depth suggests it is more than just a brief Earnings Release (ER) or a simple announcement of a report (RPA/RNS). The presence of the RNS Number (6753I) and the concluding boilerplate text from the London Stock Exchange's RNS service confirms it is a regulatory filing, but the specific content points strongly to the 'Interim / Quarterly Report' category, as it details operational progress over the preceding quarter/period.
2022-12-06 English
Subsidiary Launched and IP License Signed
M&A Activity Classification · 1% confidence The document begins with 'RNS Number : 7941D' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and 'Market Abuse Regulations (EU) No. 596/2014'. The content announces a corporate action: the launch of a new subsidiary (Cytolytix) and the signing of an IP License agreement. This type of material, which is a general, material announcement released via the London Stock Exchange's RNS system, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER), a management change (MANG), or a director's dealing (DIRS). Since it is a formal regulatory announcement distributed via RNS, RNS is the most appropriate classification.
2022-10-24 English
Issue of Share Options
Regulatory Filings Classification · 1% confidence The document is an official announcement released via RNS (RNS Number : 1613D) on October 18, 2022. The content explicitly details the 'Issue of Share Options' to a Non-executive Director (Stella Panu) and includes detailed tables regarding the vesting conditions and option grants. Crucially, the document concludes with a 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014', which is a specific regulatory requirement for disclosing insider transactions (Director's Dealing). While it involves director transactions, the primary nature of the filing, as indicated by the RNS header and the detailed transaction disclosure structure, is a regulatory disclosure concerning insider activity. This aligns best with the 'Director's Dealing' category (DIRS), which covers reports of personal share transactions by directors and executives. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a general capital change (SHA) as it specifically concerns options granted to an insider.
2022-10-18 English
Director Appointment
Board/Management Information Classification · 1% confidence The document is an official announcement from ValiRx PLC, identified by the 'RNS Number' and the reference to 'RNS, the news service of the London Stock Exchange'. The core content announces the appointment of a new Non-executive Director, Ms Stella Panu, and provides required disclosures under the AIM Rules for Companies. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The presence of 'RNS Number' and the nature of the content (Director Appointment) strongly suggests this classification over a general Regulatory Filing (RNS).
2022-10-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number' and contains the standard header/footer information associated with the London Stock Exchange's Regulatory News Service (RNS). The content details a 'TR-1: Standard form for notification of major holdings' concerning an acquisition/disposal of financial instruments by an individual shareholder, Nicholas Slater, resulting in a change in voting rights percentage (crossing below 6%). This type of mandatory disclosure regarding significant changes in share ownership thresholds is a specific regulatory filing. While it relates to shareholding changes (which could overlap with MRQ), the format and source (RNS) strongly suggest it is a general regulatory announcement. Since 'Major Shareholding Notification' (MRQ) is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)', this is the most precise fit, even though it is delivered via RNS.
2022-09-30 English
Live Shareholder Q&A and industry events
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number header and contains an announcement dated September 22, 2022. The content details an invitation for shareholders to a 'Live Shareholder Q&A' webinar and mentions participation in industry events (Bio-Europe, BioTech Outsourcing Strategies). Crucially, the document explicitly states at the end: 'This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.' Since this is a non-regulatory announcement about upcoming events and shareholder engagement, and it is not a formal financial report (like 10-K, IR, ER) or a specific corporate action announcement (like DIV, SHA, DIRS), the most appropriate classification is the general fallback for miscellaneous, non-regulatory news releases, which is Regulatory Filings (RNS), as it is distributed via the RNS system but explicitly marked as non-regulatory 'Reach'. However, given the specific content is about shareholder engagement and Q&A, it is not a standard 'Regulatory Filing' in the sense of mandatory disclosure. Since there is no specific category for 'Shareholder Event Announcement' or 'General Update', and it is explicitly distributed via RNS, RNS is the best fit among the provided options for a general, non-mandatory update distributed through the regulatory news service infrastructure.
2022-09-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.